A Phase 3 interventional study of Sugammadex and Succinylcholine in Anesthesia, General, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-04-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the trial is to demonstrate a faster recovery from neuromuscular block induced by 1.2 mg/kg rocuronium after reversal at 3 minutes by 16.0 mg/kg of sugammadex compared with recovery after a neuromuscular block induced by 1.0 mg/kg succinylcholine.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
Drug: Sugammadex · Drug: Rocuronium
Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
Drug: Succinylcholine
Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
Also known as: Org 25969, MK-8616
Single bolus IV dose of 1.0 mg/kg succinylcholine
Single bolus IV dose of 1.2 mg/kg rocuronium
Also known as: Zemuron®
Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation.
Time frame: Up to 15 minutes after administration of rocuronium + sugammadex or succinylcholine
Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation.
Time frame: Up to 20 minutes after administration of rocuronium + sugammadex or succinylcholine
Level of Consciousness: Number of Participants Awake and Oriented
The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness. The clinical level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.
Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Level of Consciousness: Number of Participants Arousable With Minimal Stimulation
The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.
Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Level of Consciousness: Number of Participants Responsive Only to Tactile Stimulation
The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.
Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Number of Participants Able to Perform 5-Second Head Lift
The number of participants who were able to lift their head for 5 seconds was assessed as a measure of recovery following neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved.
Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Number of Participants Experiencing General Muscle Weakness
The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups.
Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
| Milestone | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Started | 58 | 57 |
| Treated | 56 | 54 |
| Completed | 55 | 53 |
| Not completed | 3 | 4 |
| Withdrew: Withdrew consent | 2 | 0 |
| Withdrew: Withdrew due to surgery-related issues | 0 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Discharged prior to study completion | 0 | 1 |
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation.
| Minutes | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration | 4.35 ± 0.72 | 7.15 ± 1.55 |
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation.
| Minutes | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration | 6.13 ± 1.78 | 11.03 ± 2.40 |
The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness. The clinical level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.
| Participants | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Prior to transfer to recovery room | 8 | 13 |
| Prior to discharge from recovery room | 19 | 33 |
The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.
| Participants | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Prior to transfer to recovery room | 7 | 15 |
| Prior to discharge from recovery room | 1 | 2 |
The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.
| Participants | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Prior to transfer to recovery room | 5 | 7 |
| Prior to discharge from recovery room | 0 | 0 |
The number of participants who were able to lift their head for 5 seconds was assessed as a measure of recovery following neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved.
| Participants | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Prior to transfer to recovery room | 13 | 24 |
| Prior to discharge from recovery room | 20 | 35 |
The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups.
| Participants | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Prior to transfer to recovery room | 2 | 3 |
| Prior to discharge from recovery room | 0 | 0 |
Collected over Up to 7 days after administration of rocuronium + sugammadex or succinylcholine. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rocuronium + Sugammadex | 0/56 (0%) | 0/56 (0%) | 51/56 (91.1%) |
| Succinylcholine | 0/54 (0%) | 1/54 (1.9%) | 50/54 (92.6%) |
| Event | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Pelvic haematomaReproductive system and breast disorders | 0/56 | 1/54 |
| Event | Rocuronium + Sugammadex | Succinylcholine |
|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 32/56 | 26/54 |
| NauseaGastrointestinal disorders | 16/56 | 20/54 |
| Procedural hypotensionInjury, poisoning and procedural complications | 7/56 | 13/54 |
| VomitingGastrointestinal disorders | 9/56 | 8/54 |
| HeadacheNervous system disorders | 8/56 | 2/54 |
| ChillsGeneral disorders | 6/56 | 7/54 |
| Incision site complicationInjury, poisoning and procedural complications | 5/56 | 7/54 |
| Procedural hypertensionInjury, poisoning and procedural complications | 7/56 | 7/54 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/56 | 7/54 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/56 | 6/54 |
All participants who received study treatment
| Age, Continuous(Years) | Rocuronium + Sugammadex | Succinylcholine | Total |
|---|---|---|---|
| Mean | 42 ± 13 | 41 ± 13 | 42 ± 13 |
| Sex: Female, Male(Participants) | Rocuronium + Sugammadex | Succinylcholine | Total |
|---|---|---|---|
| Female | 33 | 31 | 64 |
| Male | 23 | 23 | 46 |
No study locations are listed for this record.
Ran from Feb 2006 to primary completion in Aug 2006, 6 months.
Results were first posted in Mar 2019, 12 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sugammadex · Rocuronium